Status:
UNKNOWN
Utility of 2- Octyl Cyanoacrylate (2-OCA)
Lead Sponsor:
Methodist Health System
Conditions:
Ascites
Fluid Loss
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Paracentesis is a commonly performed procedure in the inpatient and outpatient settings for treatment of ascites. The most frequent complication of paracentesis is fluid leak. Risk for this complicati...
Detailed Description
Paracentesis is a commonly performed procedure in the inpatient and outpatient settings for treatment of ascites. The most frequent complication of paracentesis is fluid leak. Risk for this complicati...
Eligibility Criteria
Inclusion
- Inpatients at Methodist Dallas Medical Center (MDMC) ≥18 years of age with ascites requiring therapeutic paracentesis performed by the procedure team at the bedside.
Exclusion
- Paracentesis procedures performed in the interventional radiology department or by physicians outside of the procedure team.
- Patients who undergo a liver transplant surgery or other abdominal surgeries within 48 hours from the paracentesis procedure.
- Patients that undergo paracentesis using a device or kit other than the 18 gauge Safe-T-Centesis kit
Key Trial Info
Start Date :
January 13 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 13 2024
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT05278013
Start Date
January 13 2022
End Date
January 13 2024
Last Update
July 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Dallas Medical Center Pharmacy
Dallas, Texas, United States, 75203